Overview
- The White House pulled Dr. Heidi Overton’s nomination late Tuesday, a decision that senior HHS officials and Overton’s team say blindsided them and that some learned about from an Axios report.
- Overton’s staff had just reported making concessions to win holdout Republican votes, including commitments tied to the FDA’s mifepristone review, and officials believed she had enough support to advance.
- Sen. Bill Cassidy publicly rebuked the withdrawal and warned that confirming a permanent FDA commissioner will likely fall to Senate Democrats after control shifts in January.
- Allies and people familiar with the matter say HHS Secretary Robert F. Kennedy Jr. and White House chief of staff Stephen Miller soured on Overton, and activists tied to the MAHA movement pressed for her removal.
- With acting chief Kyle Diamantas widely expected to leave by year end and no clear replacement, the FDA faces a likely extended leadership gap that could complicate the March 2027 mifepristone safety review and pending user‑fee reauthorization.